Antiproteinuric effect of candesartan cilexetil in Japanese subjects with type 2 diabetes and nephropathy

Diabetes Research and Clinical Practice
Masakazu HanedaCandesartan in Diabetic Nephropathy Study Group

Abstract

The effect of the angiotensin II receptor blocker, candesartan cilexetil, on proteinuria was examined in a prospective, multicenter, randomized, double-blind study in Japanese subjects with type 2 diabetes. This study enrolled diabetic subjects with confirmed proteinuria into four groups for 12 weeks of treatment with placebo or candesartan cilexetil 2, 4, or 8 mg. The contribution of the angiotensin converting enzyme (ACE) gene polymorphism to the effect of candesartan cilexetil was also examined. In 127 subjects, candesartan cilexetil showed a dose-related reduction in proteinuria after 12 weeks of treatment (F = 9.45, P = 0.0013), with a 18.1% reduction in the 4-mg group, and a 5.8% reduction in the 8-mg group, in contrast to a 32.2% increase in the placebo group, and a 0.8% increase in the 2-mg group. These results indicate that candesartan cilexetil is useful in reducing proteinuria in diabetic subjects when compared with placebo. In addition, candesartan cilexetil seems to be effective in subjects with both the II and DD genotypes of the ACE gene.

References

Sep 22, 2001·The New England Journal of Medicine·E J LewisUNKNOWN Collaborative Study Group
Sep 22, 2001·The New England Journal of Medicine·B M BrennerUNKNOWN RENAAL Study Investigators
Sep 22, 2001·The New England Journal of Medicine·H H ParvingUNKNOWN Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group
Aug 7, 2002·Circulation·Giancarlo VibertiUNKNOWN MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators
Feb 4, 2003·Journal of the Renin-angiotensin-aldosterone System : JRAAS·Kiyoshi KurokawaNobuya Ogawa

❮ Previous
Next ❯

Citations

Apr 18, 2009·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Hiroyuki ShimizuMasatomo Mori
Sep 27, 2005·BMJ : British Medical Journal·Michael A McDonaldRoss T Tsuyuki
Jan 28, 2010·Expert Opinion on Drug Metabolism & Toxicology·Kim TaverneOlaf Klungel
Aug 23, 2005·Diabetes/metabolism Research and Reviews
Mar 7, 2007·Diabetes Research and Clinical Practice·José A García Donaire, Luis M Ruilope
Mar 28, 2018·Journal of Diabetes Investigation·Masakazu HanedaEiichi Araki
Aug 23, 2006·Circulation·Ross T Tsuyuki, Michael A McDonald
Jun 14, 2008·Clinical Journal of the American Society of Nephrology : CJASN·Piero RuggenentiGiuseppe Remuzzi
Sep 7, 2011·Journal of Preventive Medicine and Public Health = Yebang Ŭihakhoe Chi·Sayantan BiswasTarun Sharma
Apr 9, 2016·Journal of Preventive Medicine and Public Health = Yebang Ŭihakhoe Chi·Hyungseon YeomIl Suh
Jan 31, 2009·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Mohamad M Al KhalafSuhail A R Doi
Jan 4, 2019·Diabetology International·Masakazu HanedaEiichi Araki
Aug 18, 2020·Diabetology International·Eiichi ArakiNarihito Yoshioka
Oct 7, 2020·Journal of Diabetes Investigation·Eiichi ArakiNarihito Yoshioka

❮ Previous
Next ❯

Related Concepts

Related Feeds

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Anthelmintics

Anthelmintics or antihelminthics are a group of antiparasitic drugs that expel parasitic worms (helminths) and other internal parasites from the body by either stunning or killing them and without causing significant damage to the host. Discover the latest research on anthelmintics here.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.